Lung Cancer Non-Small Cell Cancer (NSCLC)
9
2
2
1
Key Insights
Highlights
Success Rate
25% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
33.3%
3 terminated out of 9 trials
25.0%
-61.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (9)
A Lay Navigation Intervention for Patients With Lung Cancer
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
Real-World Immuno-Radiotherapy for Advanced NSCLC
Cross-sectorial Rehabilitation of Patients with Lung Cancer
Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors
Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors